Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2025—OGT launched the SureSeq Myeloid MRD Plus NGS panel, to detect ultra-low frequency variants in key measurable residual disease–associated biomarkers in acute myeloid leukemia. The panel targets 16 biomarkers associated with AML, including NPM1 and large FLT3 internal tandem duplications, and detects variants at allele frequencies as low as 0.01 percent.
Dec. 16, 2025—The Food and Drug Administration has approved additional indications for Roche’s Pathway anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody and Ventana HER2 Dual ISH DNA Probe Cocktail tests.
Dec. 15, 2025—Werfen announced its commendation of the publication of a special report underscoring the urgent need to address the risks of undetected in vitro hemolysis (Wu AHB, et al. J Appl Lab Med. 2025;10[5]:1347–1361).
Dec. 12, 2025—Natera has completed a transaction to acquire cancer diagnostics company Foresight Diagnostics.
December 2025—Randox Toxicology has launched its Nitazenes Array, an immunoassay designed to detect a broad spectrum of nitazene analogs from a single sample. The array was developed using Randox’s proprietary biochip array technology and offers a rapid turnaround time. It is available on the company’s Evidence MultiStat platform.
December 2025—BD has received FDA 510(k) clearance and CE marking for its Enteric Bacterial Panel and Enteric Bacterial Panel Plus for the BD Cor system. BD EBP offers a range of targets for enteric bacterial pathogens, including Salmonella spp., Campylobacter spp. (C. jejuni, C. coli), Shigella spp./enteroinvasive Escherichia coli, and Shiga toxin–producing E. coli. BD EBP Plus detects enterotoxigenic E. coli and heat-labile and heat-stable enterotoxin genes. The panel also identifies Plesiomonas shigelloides, Vibrio spp. (V. vulnificus, V. parahaemolyticus, V. cholerae), and Yersinia enterocolitica.
December 2025—Siemens Healthineers has introduced the Atellica DT 250 benchtop analyzer, to help identify substance use, monitor therapeutic and immunosuppressant drugs, and perform serum toxicology testing. It also offers automated specimen validity testing to detect substitution, adulteration, and dilution of urine samples. The analyzer can process 225 test results per hour and provide first results in as few as eight minutes. It features a menu of more than 65 immunoassays for use with urine, serum, and plasma samples and 10 open channels for customizable, user-defined testing.
December 2025—Primerdesign launched its Exsig Mag RapidBead Pro Extraction kit, a next-generation magnetic bead–based kit used to extract high-quality DNA and RNA from diverse sample types. The workflow reduces hands-on time compared to traditional methods and extracts DNA and RNA in less than 20 minutes.
December 2025—Bruker announced that its MALDI Biotyper CA system received expanded clearance from the FDA. The clearance includes the MBT Compass HT CA software and MBT Fast Shuttle US IVD as well as an expansion of the FDA-cleared reference library.
December 2025—Clear Labs announced at the Association for Molecular Pathology annual meeting (Boston, Nov. 11–15) its collaboration with Labcorp to automate PGDx kitted oncology NGS assays on the Clear Dx platform. Clear Labs says the collaboration aims to develop streamlined, end-to-end workflows that help laboratories improve efficiency, consistency, and throughput while laying the groundwork for future adoption across a range of genomic applications. This new workflow will expand Clear Labs’ infectious disease applications into oncology testing.
